Abstract:BACKGROUND:The purpose of this study is to evaluate the performance of recently developed tumor marker clinical kits in China, with the aim of encouraging local medical technology innovation and thus narrowing the research and development gap with foreign kits.METHODS:The newly established reagent kits were analyzed on the TESMI F3999-Luminex200 flow lattice instrument to verify precision, sensitivity (blank limit), linearity, anti-interference ability, carry-over contamination rate, hook effect, and reference interval verification. Additionally, the newly established reagent kits were compared to other commercially available detection kits (reference reagent kits) to analyze the correlation between the two types of kits.RESULTS:The intra-assay and inter-assay precision had coefficients of variations (CVs) less than 3.50% and 6.91%, respectively. The tumor marker blank limits were lower than the manufacturer's statement. The newly established reagent kits demonstrated excellent linearity (r > 0.99). Rheumatoid factor, triglycerides, bilirubin, and hemoglobin did not have significant interference with the determination of tumor markers. The carry-over contamination rates were all much lower than 3%. At extremely high concentrations of AFP (277,335 ng/mL and 1,031,424 ng/mL), the measured tumor marker values were higher than the upper limit of the linear range and no hook effect occurred. The reference interval was suitable for use in clinical laboratory settings. Correlation analysis indicated a satisfactory relevance and consistency between the newly developed reagent kits and reference reagent kits, with correlation coefficients of r > 0.967 among 654 patients and healthy individuals.CONCLUSIONS:The newly developed reagent kits for tumor markers performed well in all evaluated parameters, having the potential for clinical promotion and application.

Research Improvement of the Basis and Transformation of Tumor Markers in Clinical Laboratories

The Current Status and Future Prospects of Laboratory Biomarkers in the Diagnosis of Liver Cancer

Advances in Research on Application of Tumor Markers and Their Screening Technique

Changes Of Tumor Markers And C Reactive Protein In Different Status Of Lung Cancer

Improving the diagnosis and treatment of biliary malignant tumor

Research Progress of Translational Medicine Based on Tumor Molecular Biomarkers

Analysis and Future Perspectives of the Grants Funded by National Natural Science Foundation of China on Tumor Biomarker Research in Laboratory Medicine from 2010 to 2018

Tumor Treatment Based on Translational Medicine

[Advances in Basic and Translational Research in Neuroendocrine Neoplasms].

[Ten Directions for Improving Clinical Therapeutic Effect of Pancreatic Cancer in the Future].

Research advance of metabonomics in tumor markers of lung cancer

Bibliometrics Analysis of Traditional Chinese Medicine of Tumor

Research Progress of CDT.

Tumor biomarkers for diagnosis, prognosis and targeted therapy

Application and advances of detection technology for tumor markers

Performance Evaluation of Newly-Developed Tumor Markers Assay Kit Based on Flow Fluorescence Assay.

Important Issues of Cancer Metastasis

Cancer Molecular Epidemiology and Tumor Markers

Hotspots in basic and translational research of gastric cancer

Advances in molecular biological indicators for prognosis in pancreatic cancer

Advances in Basic Research, Clinical Diagnosis and Treatment of Pancreatic Cancer in 2020